Time Is Ripe For Global Action On Orphan Biosimilars

Industry Urges Incentives And Tailored Pricing And Reimbursement Policies

 
• By Francesca Bruce
  
Generate a summary of this article
Listen to this article
Beta

European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.

Abstract mash line and point scales on dark background with Map World. Wire Frame 3D mesh polygonal network line, design sphere, dot and structure. Vector illustration eps 10
Medicines for Europe calls for International collaboration on biosimilar orphans • Source: Shutterstock

As the European Commission focuses on its orphan legislation and pledges to improve access to medicines, now is the right time to act to develop a new environment that will incentivize the development of biosimilar orphans, says Medicines For Europe, the association that represents the generic medicines industry in Europe. The association has called for more incentives and a tailored pricing and reimbursement approach.

Biosimilar versions of orphan drugs could make big savings for cash strapped health care systems and boost access to medicines.(Also...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C7

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C6

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

US Biosimilars

An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

More from Products

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

Biocon And Teva Sign Up To Biosimilars Forum

Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.